JHU–Pfizer CTI Frequently Asked Questions

JHU–Pfizer CTI
Frequently Asked Questions


JHU–Pfizer CTI HOME | CTI Proposal Process
JHU and Pfizer CTI Joint Steering Committee | Frequently Asked Questions

 

 

 

When will Johns Hopkins University investigators have the opportunity to submit CTI pre-proposals?

CTI program has two calls for proposals each year. The next scheduled call will close on October 13, 2017. Learn more about the CTI call for proposals.

What types of projects are of interest for CTI development?

Each call for proposals may contain different areas of therapeutic focus. Review the therapeutic areas of interest to explore the types of projects appropriate for CTI.

Are Pfizer scientists going to work at The Johns Hopkins University?

The agreement allows the flexibility for scientists from both organizations to work at each other’s facilities.

Who will own the intellectual property (IP) discovered through this project? If Pfizer commercializes a compound produced through this collaboration, how will The Johns Hopkins University receive compensation?

Pfizer has the first right of refusal to exclusively license IP for a Clinical Probe developed under the Johns Hopkins University and CTI agreement. However, if Pfizer decides not to license a jointly developed Clinical Probe, The Johns Hopkins University has the option of licensing that Clinical Probe for development by another company.

Research rights are not compromised by this collaboration. Should Pfizer decide not to move forward with a project, The Johns Hopkins University still owns all the background IP that it brought to the partnership, and the investigator may continue his or her research independently from CTI.

Who do I contact if I have questions about this program?

Johns Hopkins University investigators should contact Sean Evans at Johns Hopkins Technology Ventures or Nader Halim at CTI for more information.